Business
Axcan announces conference call and webcast for third quarter of fiscal 2005 results
Axcan announces conference call and webcast for third quarter of fiscal 2005 results.
About this update from Trailbreaker Resources Ltd
[{"type":"text","content":"\n\n\n\n\nTSX SYMBOL (Toronto Stock Exchange): AXP\nNASDAQ SYMBOL (Nasdaq National Market): AXCA\n\nMONT SAINT-HILAIRE, QC, Aug. 2 /CNW Telbec/ - Axcan Pharma Inc. (\"Axcan\"\nor the \"Company\") today announced that it will report financial results for\nthe third quarter of fiscal 2005 ended June 30, 2005, on Thursday, \nAugust 11, 2005.\nAxcan will host a conference call at 5:00 P.M. ET, on August 11, 2005.\nInterested parties may also access the conference call by webcast at\nwww.axcan.com . The webcast will be archived for 90 days.\nThe telephone numbers to access the conference call are (866) 250-4910\n(Canada and United States) or (416) 640-4127 (international). A replay of the\ncall will be available until August 18, 2005. The telephone number to access\nthe replay of the call is (416) 640-1917 code: 21133243.\n\nAxcan is a leading specialty pharmaceutical company involved in the field\nof gastroenterology. The Company markets a broad line of prescription products\nsold for the treatment of symptoms in a number of gastrointestinal diseases\nand disorders such as inflammatory bowel disease, irritable bowel syndrome,\ncholestatic liver diseases and complications related to cystic fibrosis.\nAxcan's products are marketed by its own sales force in North America and\nEurope. Its common shares are listed on the Toronto Stock Exchange under the\nsymbol \"AXP\" and on the NASDAQ National Market under the symbol \"AXCA\".\n\n\"Safe Harbor\" statement under the Private Securities Litigation Reform\n----------------------------------------------------------------------\nAct of 1995.\n------------\n\nTo the extent any statements made in this release contain information\nthat is not historical, these statements are essentially forward looking and\nare subject to risks and uncertainties, including the difficulty of predicting\nFDA and other regulatory approvals, acceptance and demand for new\npharmaceutical products, the impact of competitive products and pricing, new\nproduct development and launch, reliance on key strategic alliances,\navailability of raw materials, the regulatory environment, fluctuations in\noperating results and other risks detailed from time to time in the Company's\nfilings with the Securities and Exchange Commission and the Canadian\nMultijurisdictional Disclosure System.\n\n\n","length":2366,"tagName":"div"}]